Vaccines are not sold to the general public.
They can only be administered by a Veterinarian following a thorough examination of the animal.
Nobivac DHPPi is a core vaccine that contains live attenuated canine distemper virus, canine adenovirus (CAV-2), canine parvovirus (C154) and canine parainfluenza virus.
Core Canine Vaccination
Vaccination is an integral part of a preventative health care programme. Every dog should be vaccinated against 3 core diseases – canine distemper, infectious hepatitis and canine parvo virus. These diseases can have devastating consequences for a dog and it is easy to prevent them by regular vaccination.
Leading technology for premium protection
Intervet/Schering-Plough Animal Health has been a world leader in research and development of canine vaccines for over 20 years. In 1987, the first “high titre, low passage” vaccine against parvovirus – Nobivac ParvoC – was launched containing a patented strain of parvovirus called C154. The vaccine was the first parvo vaccine able to break through levels of maternally-derived antibodies. It was a revolution in canine vaccination.
Today, the Nobivac range still provides leading technology and premium parvo protection with vaccines that now provide proven protection against all known types of canine parvovirus (including types 2a, 2b and 2c), protection in puppies from as early as 10 weeks of age, and the convenience of single vaccination in dogs with unknown vaccination histories.